OncoMatch/Clinical Trials/NCT04904653
The Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage
Is NCT04904653 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Hemopatch for hemopatch.
Treatment: Hemopatch — Hemopatch is an alternative to reduce morbidity associated with axillary lymphadenectomy surgery, possibly contributing to improved patient management, clinical outcomes, and hospital costs. We propose a multicenter, controlled, and randomized trial to study the efficacy of Hemopatch in reducing serous wound drainage.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Prior therapy
Cannot have received: radiation therapy
Previous radiation therapy
Cannot have received: axillary emptying
Previous axillary emptying
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify